Trial Profile
A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Moxetumomab pasudotox (Primary)
- Indications Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions
- Sponsors MedImmune
- 04 Jun 2019 Results assessing pooled safety summary for patients treated with the CD22-directed cytotoxin moxetumomab pasudotox-tdfk presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 08 Feb 2017 New trial record